by MM360 Staff | Jul 19, 2025 | Uncategorized
Source: CureToday articles The FDA’s Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple myeloma patient population. Read More
by Matthew Shinkle | Jul 18, 2025 | Uncategorized
An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used in the proposed dosages for previously treated adult patients with relapsed/refractory multiple myeloma.The FDA Oncologic Drugs Advisory...
by MM360 Staff | Jul 17, 2025 | Uncategorized
Source: CureToday articles Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how incidental back pain led to an unexpected cancer diagnosis, the initial shock and fear that followed, and the pivotal...
by MM360 Staff | Jul 17, 2025 | Uncategorized
Source: CureToday articles Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving clinical data—highlighting the shift toward a comprehensive, multi-phase approach that begins with a four-drug induction...
by MM360 Staff | Jul 16, 2025 | Uncategorized
Source: CureToday articles The program emphasized the importance of incorporating patient and caregiver perspectives alongside clinical expertise to support personalized, empathetic care and shared decision-making in managing the diverse and complex challenges of...
by MM360 Staff | Jul 16, 2025 | Uncategorized
Source: CureToday articles Panelists discuss the multifaceted diagnostic process for multiple myeloma, emphasizing the integration of blood tests, genetic and imaging assessments, and patient education to guide personalized treatment planning and enhance patient...
